#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Lymphangiomatosis – very rare disease of the lymphatic vessels


Authors: Zdeněk Král 1;  Marta Krejčí 1;  Ivana Červinková 2;  Luděk Pour 1;  Martin Štork;  Martin Krejčí 1;  Viera Sandecká 1;  Zdeněk Adam 1
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1;  Klinika dětské radiologie LF MU a FN Brno 2
Published in: Vnitř Lék 2021; 67(E-4): 9-12
Category: Review Articles

Overview

Lymphangiomatosis is rare disease, we can find this entity in differential diagnosis of osteolytic leasions of bones of unknown origin. Typical sign for lymphangiomatosis is proliferation of lymphatic tissue with production of lymphangiomas in various organs and systems. Clinical manifestation of disease is variable, involvement of lungs and bone is typical. In our article we present recent classification of lymphatic tissue neoplasias, their clinical symptoms and treatment possibilities.

Keywords:

lymphangiomatosis


Sources

1. Navrátilová Z, Štěrba J. Lymfangiomatóza skrota, břišní stěny a dolních končetin LYMPHO. Praha: AMCA. 2012: s. 26.

2. Lukeš J, Dort V, Kohoutek V. Kostní systémová lymfangiomatóza. Československá pediatrie. 1973; 28: 417–419.

3. Krásný J Baráková D, Chodounský Z et al. Lymfangiom orbitopalpebrální oblasti. Česká a slovenská oftalmologie. 2014; 70: 152–159.

4. Rygl M, Šnajdauf J, Pýcha K et al. Abdominální lymfangiomy v dětském věku. Rozhledy v chirurgii. 2000; 79: 609–612.

5. International Society for the Study of Vascular Anomalies: ISSVA classification for vascular anomalies (approved at the May 2018 General Assembly in Amsterdam, the Netherlands). http://issva.org/classification (last accessed June 2018).

6. Trenor CC, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg 2014; 23: 186–190.

7. Blei F. Lymphangiomatosis: clinical overview. Lymphat Res Biol. 2011; 9: 185–190.

8. Adams DM, Ricci KW. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options. Hematol Oncol Clin North Am 2019; 33(3): 455–470.

9. Ozeki M, Fukao T. Generalized lymphatic anomaly and Gorham-Stout disease: overview and recent insights. Adv Wound Care (New Rochelle) 2019; 8: 230–245.

10. Greene AK, Goss JA. Vascular anomalies: from a clinicohistologic to a genetic framework. Plast Reconstr Surg 2018; 141: 709e–717e.

11. Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014; 124: 898–904.

12. Osborn AJ, Dickie P, Neilson DE et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet 2015; 24: 926–938.

13. Boscolo E, Coma S, Luks VL et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis 2015; 18: 151–162.

14. Manevitz-Mendelson E, Leichner GS, Barel O et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis 2018; 21: 287–298.

15. Yerganyan VV, Body JJ, De Saint Aubain N, Gebhart M. Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 2015; 16: 42–46.

16. Hammer F, Kenn W, Wesselmann U et al. Gorham-Stout disease – stabilization during bisphosphonate treatment. J Bone Miner Res. 2005; 20: 350–353.

17. Kato H, Ozeki M, Fukao T, Matsuo M. MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis. Jpn J Radiol 2017; 35: 606–612.

18. Kuriyama DK, McElligott SC, Glaser DW et al. Treatment of Gorham–Stout disease with zoledronic acid and interferon-alpha: a case report and literature review. J Pediatr Hematol Oncol 2010; 32: 579–584.

19. Ozeki M, Funato M, Kanda K et al. Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature. Pediatr Hematol Oncol 2007; 24: 513–524.

20. Grunewald TG, Damke L, Maschan M et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham–Stout) with bevacizumab in a child. Ann Oncol 2010; 21: 1733–1734.

21. Ozeki M, Fukao T, Kondo N. Propranolol for intractable diffuse lymphangiomatosis. N Engl J Med 2011; 364: 1380–1382.

22. Hammill AM, Wentzel M, Gupta A et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57: 1018–1024.

23. Lackner H, Karastaneva A, Schwinger W et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174: 1579–1584.

24. Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope 2011; 121: 1851–1854.

25. Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137: 1–10.

26. Nadal M, Giraudeau B, Tavernier E et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereo 2016; 96: 448–452.

27. Itkin M. Interventional treatment of pulmonary lymphatic anomalies. Tech Vasc Interv Radiol 2016; 19: 299–304.

28. Heyd R, Micke O, Surholt C et al. German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). Radiation therapy for Gorham–Stout syndrome: results of a national patterns-of-care study and literature review. Int J Radiat Oncol Biol Phys 2011; 81: 179–185.

29. Dunbar SF, Rosenberg A, Mankin H, Rosenthal D, Suit HD. Gorham's massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 1993; 26: 491–497.

30. Müller-Wille R, Wildgruber M, Sadick M et al. Vascular Anomalies (Part II): Interventional therapy of peripheral vascular malformations. Rofo 2018; 190: 927–937.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#